StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
August 31, 2026 9:20 AM
Stifel analyst Paul Matteis reiterated a Buy rating and $318.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented, "Coming ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
